You are here

bb2121

Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive

Reuters

Sat, 01/11/20 - 12:06 am

Bristol-Myers Squibb

BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS

Fierce Pharma

Sun, 11/24/19 - 11:35 pm

Bristol-Myers Squibb

Where Will bluebird bio Be in 1 Year?

Motley Fool

Fri, 06/21/19 - 09:58 am

Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses

Fierce Biotech

Fri, 05/3/19 - 10:45 am

Multiple Myeloma

bluebird bio to Cut Ribbon on New Gene Therapy Factory in Durham, NC; Plans to Hire

BioSpace

Fri, 03/22/19 - 10:06 pm

drug manufacturing

Celgene to launch five new products through to 2020

PM Live

Mon, 10/29/18 - 07:02 pm

Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

Motley Fool

Fri, 09/14/18 - 11:59 pm

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Fierce Biotech

Fri, 07/13/18 - 09:44 am

clinical trials

Multiple Myeloma

Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet

Forbes

Fri, 06/1/18 - 10:48 pm

Multiple Myeloma

Celgene, bluebird revise deal to co-develop CAR-T therapy

Biopharma Dive

Thu, 03/29/18 - 11:33 am

drug development

Multiple Myeloma

How Celgene Hopes to Cash In on CAR-T

Yahoo/Motley Fool

Sat, 02/17/18 - 10:41 am

As CAR-Ts go from candidates to brands, what's the marketing strategy?

Medical Marketing and Media

Tue, 02/13/18 - 09:01 am

Juno Therapeutics

JPM18: bluebird set to file 3 drugs for approval by 2019

Biopharma Dive

Wed, 01/10/18 - 10:21 am

Celgene Shareholders Excited by CAR-T News

Motley Fool

Tue, 12/19/17 - 08:10 pm

bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results

Motley Fool

Mon, 12/11/17 - 10:02 am

Multiple Myeloma

Why bluebird bio Inc Continued Its March Higher Again Today

Motley Fool

Thu, 08/31/17 - 10:13 pm

Gilead Sciences

Is This Why bluebird bio Dipped 10.5% in July?

Motley Fool

Wed, 08/9/17 - 09:35 am

Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?

Investors Business Daily

Sun, 07/2/17 - 10:07 am

Juno Therapeutics

immuno-oncology

Bluebird Bio: Too Much Good News?

Barron's

Sat, 07/1/17 - 09:31 am

Bluebird has a promising new update on its BCMA CAR-T for multiple myeloma, but is it still the leader?

Endpoints

Mon, 06/5/17 - 12:10 pm

Multiple Myeloma

Pages